La Jolla Pharmaceutical Company Doses First Patient in Phase 1 Clinical Trial ... - MarketWatch

La Jolla Pharmaceutical Company Doses First Patient in Phase 1 Clinical Trial ... MarketWatch SAN DIEGO, Oct 19, 2015 (BUSINESS WIRE) -- La Jolla Pharmaceutical Company LJPC, +4.27% (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from ... and more »

from phlebotomy - Google News http://bit.ly/1LyUQ3l